Ten years have passed since Oryzon Genomics – a biopharmaceutical company specialized in epigenetics for the development of innovative therapies in oncology/hematology and central nervous system (CNS) disorders – made its debut on the Spanish stock market. Since then, the company has experienced a decade of growth, innovation, and commitment to advancing biomedical research.
The Company
On November 14, 2015, Oryzon joined the main market of Bolsas y Mercados Españoles (BME), becoming the first Spanish biotech company to be listed on the country’s main exchange. Its goal was to strengthen its growth strategy, enhance international visibility, and attract new investors to support the clinical development of its next-generation epigenetic drugs.
Since its listing, Oryzon has built a solid track record in research and development, with a robust pipeline of products in various clinical stages and strategic collaborations with international partners. According to the latest published results, corresponding to the period between January 1 and September 30, 2025, the company maintains Development intangible assets amounting to 146 million euros, shareholders’ equity of 117 million euros, and available cash of 34 million euros..
In the stock market, Oryzon’s share performance reflects investors’ confidence in its business model and long-term vision, this year the company’s share price has appreciated by 100%, rising from €1.5 to €3.2 per share, making it one of the most attractive stocks in the IBEX SMALL CAP and in the Spanish continuous market as a whole, with an approximate market capitalization of around €260 million.
Reaching ten years on the Spanish Stock Exchange marks a significant milestone in Oryzon’s trajectory. This anniversary reflects the strength of our commitment to biomedical research, scientific excellence, and responsible innovation. We are grateful for the market’s confidence and reaffirm our determination to continue driving the growth of Spanish biotechnology in international markets
Carlos Buesa, CEO of Oryzon Genomics
The Role of BME’s Main Market
Oryzon’s incorporation into the main market of BME marked a milestone for the Spanish biotechnology sector, paving the way for other innovative companies seeking financing and visibility through the capital markets.
BME’s main market offers companies a regulated, transparent, and well-supervised environment that enables them to access the financing they need to continue growing and innovating, while contributing to the development of the Spanish business ecosystem.
Over the past decade, Oryzon has demonstrated how the combination of scientific excellence, entrepreneurial vision, and access to capital markets can drive sustainable growth and create value for shareholders, employees, and society as a whole.